SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-211213"
 

Search: onr:"swepub:oai:DiVA.org:uu-211213" > Selecting deep brai...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Volkmann, J (author)

Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease : an evidence-based review

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2013-01-05
  • Springer Science and Business Media LLC,2013
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-211213
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-211213URI
  • https://doi.org/10.1007/s00415-012-6798-6DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:127678707URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Motor complications in Parkinson’s disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine. 

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Albanese, A (author)
  • Antonini, A (author)
  • Chaudhuri, KR (author)
  • Clarke, CE (author)
  • de Bie, RM (author)
  • Deuschl, G (author)
  • Eggert, K (author)
  • Houeto, JL (author)
  • Kulisevsky, J (author)
  • Nyholm, DagUppsala universitet,Neurologi(Swepub:uu)danyh856 (author)
  • Odin, P (author)
  • Ostergaard, K (author)
  • Poewe, W (author)
  • Pollak, P (author)
  • Rabey, JM (author)
  • Rascol, O (author)
  • Ruzicka, E (author)
  • Samuel, M (author)
  • Speelman, H (author)
  • Sydow, OKarolinska Institutet (author)
  • Valldeoreola, F (author)
  • van der Linden, C (author)
  • Oertel, W (author)
  • Uppsala universitetNeurologi (creator_code:org_t)

Related titles

  • In:Journal of Neurology: Springer Science and Business Media LLC260:11, s. 2701-27140340-53541432-1459

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view